Aging, IGF-1, and diet

Michael Pollak

Department of Oncology, McGill University, Montreal, Quebec, Canada

Fontana *et al.* (2008) recently reported in *Aging Cell* their interesting findings, based on studies of 46 subjects, of the impact of chronic severe caloric restriction on insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels. They concluded that protein intake may be a more important determinant of the circulating levels than energy restriction, and speculated that this may have implications with respect to longevity.

We previously reported (Holmes *et al.*, 2002; Giovannucci *et al.*, 2003) studies of 1037 women and 753 men that explored dietary determinants of IGF-1 and IGFBP-3 levels in a cross-section of subjects on typical North American diets. We observed, in females, a positive association between protein intake with circulating IGF-1 concentration (174, 188, 201, 192, and 196 ng mL⁻¹ across quintiles of protein intake; *p* = 0.002), which was stronger than the relationship between energy intake and IGF-1 concentration. Similar findings were seen in men, where the relationship of energy intake to IGF-1 levels was seen only in men with body mass index < 25 kg m⁻². Thus, the intervention study involving a small number of subjects by Fontana *et al.* yielded data consistent with the larger observational studies we previously reported.

Correspondence

Caution is required in extrapolating data concerning dietaryinduced changes in IGF-1 levels to changes in health outcomes, such as longevity or cancer risk. While there is clear evidence that reduced IGF signalling is associated with increased longevity in model organisms, there is evidence that lower IGF-1 levels are associated with increased cardiovascular disease in humans (Brugts *et al.*, 2008). In addition, recent data (e.g. Ma *et al.*, 2008) suggest that with respect to cancer endpoints, it is important to consider insulin levels as well as IGF-1 levels. The relationships between diet, insulin and IGF-1 levels, and clinical health outcomes is an important topic, but one that appears to be more complex than might have been implied by animal models.

References

- Brugts MP, van den Beld AW, Hofland LJ, van der Wansem K, van Koetsveld PM, Frystyk J, Lamberts SW, Janssen JA (2008) Low circulating insulinlike growth factor I bioactivity in elderly men is associated with increased mortality. J. Clin. Endocrinol. Metab. 93, 2515–2522.
- Fontana L, Weiss EP, Villareal DT, Klein S, Holloszy JO (2008) Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans. *Aging Cell* 7, 681–687.
- Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, Willett WC (2003) Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. *Cancer Epidemiol. Biomarkers Prev.* **12**, 84–89.
- Holmes MD, Pollak MN, Willett WC, Hankinson SE (2002) Dietary correlates of plasma insulin-like growth factor I and insulin-like growth factor binding protein 3 concentrations. *Cancer Epidemiol. Biomarkers Prev.* **11**, 852–861.
- Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ (2008) Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. *Lancet Oncol.* 9, 1039–1047.

Michael Pollak, Department of Oncology, McGill University, Montreal, Quebec, Canada. Tel.: 514-340-8222 ext. 4139; fax: 514-340-8600; e-mail: michael.pollak@mcgill.ca